Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Talk outline
- HLA class I antigen processing in tumors
- Heterogeneous HLA class I antigen expression
- HLA class I abnormalities
- HLA class I downregulation in different tumors
- Reasons for downregulation differences
- Selective pressure & HLA class I negative cells
- Human malignant lesions in SCID mice
- HLA class I downregulation & TAA specific CTLs
- HLA-A2 loss and recurrence of metastases
- Types of HLA class I defects
- b2m gene mutations in human melanoma cell lines
- Lack of HLA-A2 expression
- ERK1/2 in melanoma cells with BRAF-mutated
- Chemotherapy & HLA class I upregulation
- Radiation therapy & HLA class I upregulation
- HLA class I & link to disease free intervals
- HLA class I expression & TILs
- Conclusions
Topics Covered
- HLA class I antigen processing and expression in tumors
- HLA class I changes and their impact on tumor cell/immune system interactions
- Radiation and chemo therapy enhancement of anti-tumor host immune response
- Effects of HLA class I changes on disease clinical course & immune therapy response
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Ferrone, S. (2015, June 30). HLA class I antigen defects in malignant cells - functional and clinical relevance [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 8, 2024, from https://doi.org/10.69645/OVKN8666.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Soldano Ferrone has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Immunotherapy of Cancer
Transcript
Please wait while the transcript is being prepared...
0:00
I am Soldano Ferrone,
and I hold a faculty position at the Massachusetts General Hospital,
Harvard Medical School in Boston, Massachusetts, United States.
My research interest in the area of tumor immunology,
and especially in the mechanisms which are utilized by tumor cells
in order to escape recognition and destruction by the host immune system.
0:27
Over the years, I have investigated
how tumor cells change the expression of HLA class I and class II antigens
and how these changes impact
the interaction of tumor cells which hurts the immune system
and as a result, also on the clinical course of the disease
and on the response to immunotherapeutic strategies.
Now, today, I would like to discuss with you the changes which have been identified in
the expression and function of HLA class I antigen
processing machinery in malignant cells.
As you know, in human, unlike the animal species,
when cells undergo malignant transformation,
a number of changes occur,
and the changes involve the morphology,
the rate of proliferation,
and the expression of antigen,
just to mention a few.
Among the changed molecules are
the HLA class I antigens.
1:34
The reason why histocompatibility antigens
play such an important role is represented by the fact that
they are involved in the generation and presentation of
peptides from tumor antigens to the host immune system.
This function is played by
the antigen processing machinery which works in the following way.
In a very schematic and simple way,
the antigen processing machinery first cleaves tumor antigens,
and these are mostly endogenous proteins, into peptides,
which have the size of 9,11 amino acids long,
and which are transported by the transporter
associated with antigen processing to the endoplasmic reticulum.
In the endoplasmic reticulum,
the peptides are loaded on HLA class I antigens,
which are composed of a heavy chain non-covalently associated with the polypeptide,
which has been identified as Beta-2 microglobulin.
Now, the loading of the peptides on the dimer composed of HLA class I heavy chain
and Beta-2 microglobulin takes place with the help of several chaperone molecules,
whose function is to be sure that
the loading of the peptide on the HLA class I and
Beta-2 microglobulin dimer occurs in an optimal way since abnormalities
in these peptides may have
a negative impact on the presentation of the peptides to the immune system.
Now, once the peptide has been loaded on
the HLA class I heavy chain Beta-2 microglobulin complex,
the resulting trimolecular complex goes through the Golgi apparatus
and travels to the cell membrane where the presenting is done in the right way;
the peptide is presented to cognate CTL,
which will recognize the peptide,
will become activated, and will lyse the target cells.
It has been found that the complex of
antigen processing machinery may
undergo changes when cells undergo a malignant transformation.
These changes may be represented either by downregulation in the expression of
the components of the antigen processing machinery
or in the lack of expression of these components.
From a functional viewpoint,
that will result in an effective synthesis and
expression of the HLA class I to more antigen peptide complex.
Now, I'd like to first ask the question, well,
how do we identify the changes in the expression of
the HLA class I antigen processing machinery components in malignant cells?
This is done mainly by utilizing immunohistochemical staining of
tissue sections with antibodies which are specific for
the components of the antigen processing machinery.
The slide gives some examples of the staining of
Hide